⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NKTR News
Nektar Therapeutics
IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
globenewswire.com
FATE
INDP
AMGN
NKTR
IBIO
TAK
SNY
INMB
CLMT
VERX
GTBP
BHVN
CHRS
GSK
BMY
MRK
ABBV
AZN
GILD
LLY
KYMR
REGN
SPRY
Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
prnewswire.com
NKTR
Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering
prnewswire.com
NKTR
Nektar Therapeutics Announces Proposed Public Offering
prnewswire.com
NKTR
New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing
prnewswire.com
NKTR
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
prnewswire.com
NKTR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
accessnewswire.com
NKTR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
accessnewswire.com
NKTR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
accessnewswire.com
NKTR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
accessnewswire.com
NKTR